PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PEPG PepGen Inc.

Not Yet Opened 05-19 16:00:00 EDT

1.38

-0.09

-6.12%

盘后1.47

+0.09+6.39%

19:26 EDT

High1.47	Low1.37	Vol842.34K
Open1.45	D1 Closing1.47	Amplitude6.46%
Mkt Cap95.38M	Tradable Cap63.17M	Total Shares69.12M
T/O1.19M	T/O Rate1.84%	Tradable Shares45.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PEPG","market":"US","secType":"STK","nameCN":"PepGen Inc.","latestPrice":1.38,"timestamp":1779220800000,"preClose":1.47,"halted":0,"volume":842337,"hourTrading":{"tag":"盘后","latestPrice":1.4682,"preClose":1.38,"latestTime":"19:26 EDT","volume":6575,"amount":9605.9861,"timestamp":1779233163591,"change":0.0882,"changeRate":0.063913,"amplitude":0.073696},"delay":0,"changeRate":-0.06122448979591842,"floatShares":45776899,"shares":69115292,"eps":-1.511087,"marketStatus":"Not Yet Opened","change":-0.09,"latestTime":"05-19 16:00:00 EDT","open":1.45,"high":1.465,"low":1.37,"amount":1186723.5342704998,"amplitude":0.064626,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.511087,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779264000000},"marketStatusCode":0,"adr":0,"listingDate":1651809600000,"exchange":"NASDAQ","adjPreClose":1.47,"preHourTrading":{"tag":"盘前","latestPrice":1.47,"preClose":1.47,"latestTime":"09:29 EDT","volume":396,"amount":589.129992,"timestamp":1779197399030,"change":0,"changeRate":0,"amplitude":0.07483},"postHourTrading":{"tag":"盘后","latestPrice":1.4682,"preClose":1.38,"latestTime":"19:26 EDT","volume":6575,"amount":9605.9861,"timestamp":1779233163591,"change":0.0882,"changeRate":0.063913,"amplitude":0.073696},"volumeRatio":0.849563,"impliedVol":1.2517,"impliedVolPercentile":0.6335},"requestUrl":"/m/hq/s/PEPG/wiki","defaultTab":"wiki","newsList":[{"id":"2636633798","title":"PepGen Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2636633798","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636633798?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:23","pubTimestamp":1779207808,"startTime":"0","endTime":"0","summary":"PepGen  filed a registration statement Monday for the potential sale of up to $400 million of securities from time to time.The filing covers common and preferred stocks, debt securities, warrants, and units.Net proceeds will be used for general corporate purposes, the company said.Price: 1.41, Change: -0.06, Percent Change: -4.08","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636872863","title":"PepGen files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2636872863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636872863?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:10","pubTimestamp":1779207009,"startTime":"0","endTime":"0","summary":"12:08 EDT PepGen (PEPG) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-files-400m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636868496","title":"PepGen Inc - Files to Offer up to $400 Mln in Securities From Time to Time - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636868496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636868496?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:04","pubTimestamp":1779206658,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41W0MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636868495","title":"PepGen Inc - New Sales Agreement Replaces Prior Sales Agreement; Prior Agreement Terminated - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636868495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636868495?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:04","pubTimestamp":1779206658,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41W0MC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636386849","title":"PepGen Inc - May Sell up to $100 Mln Common Stock Under Atm Agreement With Stifel - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636386849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636386849?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:04","pubTimestamp":1779206658,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41W0MC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635873601","title":"PepGen price target lowered to $4 from $5 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2635873601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635873601?lang=en_us&edition=fundamental","pubTime":"2026-05-13 23:25","pubTimestamp":1778685932,"startTime":"0","endTime":"0","summary":"Wedbush analyst Laura Chico lowered the firm’s price target on PepGen (PEPG) to $4 from $5 and keeps an Outperform rating on the shares. Most impor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pepgen-price-target-lowered-to-4-from-5-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pepgen-price-target-lowered-to-4-from-5-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635735160","title":"PepGen Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2635735160","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635735160?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:50","pubTimestamp":1778683800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PEPG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 10:50 ET (14:50 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635911780","title":"Wedbush Trims Price Target on PepGen to $4 From $5, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2635911780","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635911780?lang=en_us&edition=fundamental","pubTime":"2026-05-13 21:26","pubTimestamp":1778678790,"startTime":"0","endTime":"0","summary":"PepGen (PEPG) has an average rating of buy and mean price target of $10, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635827887","title":"Wedbush Keeps Their Buy Rating on PepGen Inc. (PEPG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635827887","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635827887?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:37","pubTimestamp":1778675853,"startTime":"0","endTime":"0","summary":"Wedbush analyst Laura Chico maintained a Buy rating on PepGen Inc. today and set a price target of $4.00. According to TipRanks, Chico is a 5-star ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-pepgen-inc-pepg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635372223","title":"PepGen Q1 EPS $(0.26) Beats $(0.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635372223","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635372223?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:06","pubTimestamp":1778619996,"startTime":"0","endTime":"0","summary":"PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 71.74 percent increase over losses of $(0.92) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52508906/pepgen-q1-eps-0-26-beats-0-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"PepGen Q1 EPS $(0.26) Beats $(0.31) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635240224","title":"PepGen Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635240224","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635240224?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:30","pubTimestamp":1778617846,"startTime":"0","endTime":"0","summary":"PepGen Inc reports results for the quarter ended March 31 - Earnings SummaryPepGen Inc PEPG.OQ reported a quarterly adjusted loss of 26 cents per share for the quarter ended March 31, higher than the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P331:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635778247","title":"PepGen Q1 loss narrows as operating expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2635778247","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635778247?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:14","pubTimestamp":1778616862,"startTime":"0","endTime":"0","summary":"PepGen Q1 loss narrows as operating expenses fallOverviewUS biotechnology firm's Q1 net loss narrowed yr/yr as operating expenses declinedCompany ended Q1 with $132.3 mln in cash, seen funding operati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P1DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247933","title":"PepGen Q1 FY26 net loss narrows to $17.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247933","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247933?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:06","pubTimestamp":1778616408,"startTime":"0","endTime":"0","summary":"PepGen posted a net loss of USD 17.8 million, or USD 0.26 per share, for quarter ended March 31, 2026, narrowing from a net loss of USD 30.2 million, or USD 0.92 per share, a year earlier.R&D expense fell to USD 13 million from USD 25.4 million, while G&A held flat at USD 5.9 million.Cash, cash equivalents and marketable securities slid to USD 132.3 million at March 31, 2026, from USD 148.5 million at Dec. 31, 2025; funding seen lasting into second half of 2027.FREEDOM2 10 mg/kg cohort for PGN-EDODM1 in DM1 is fully enrolled, with data expected in second half of 2026; 5 mg/kg cohort showed favorable safety, splicing and vHOT data.FDA placed a partial clinical hold tied to previously submitted preclinical pharmacology and toxicology studies, with timing of ongoing FREEDOM2 study unchanged.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL5b4cb2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247511","title":"BRIEF-PepGen Q1 EPS USD -0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247511","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247511?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616346,"startTime":"0","endTime":"0","summary":"BRIEF-PepGen Q1 EPS USD -0.26\n\n\nMay 12 (Reuters) - PepGen Q1 operating expenses USD 18.942 million.\n\nQ1 net income USD -17.763 million\nQ1 operating income USD -18.942 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLXA50B04:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635247947","title":"Press Release: PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635247947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635247947?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:05","pubTimestamp":1778616300,"startTime":"0","endTime":"0","summary":"-- FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort --. -- The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 --. -- Well-funded with $132.3M of cash as of March 31, 2026, sufficient to fund operations through FREEDOM2 12.5 mg/kg MAD readout and into 2H 2027 --. \"We made encouraging progress during the first quarter of 2026 in our FREEDOM2-DM1 trial. The 5 mg/kg cohort -- the initial dose cohort -- demonstrated a favorable tolerability profile and promising efficacy trends, reinforcing our confidence in PGN-EDODM1's potential at higher doses,\" said James McArthur, PhD, President and Chief Executive Officer of PepGen. \"Enrollment in the 10 mg/kg cohort is now complete and we remain on track to report data in the second half of this year. With funding in place through the 10 and 12.5 mg/kg cohorts, we are well positioned to continue dose ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632330955","title":"PepGen Inc  expected to post a loss of 31 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632330955","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632330955?lang=en_us&edition=fundamental","pubTime":"2026-05-04 20:57","pubTimestamp":1777899427,"startTime":"0","endTime":"0","summary":"PepGen Inc  expected to post a loss of31cents a share - Earnings Preview PepGen Inc PEPG.OQ PEPG.O is expected to  show no change in quarterly revenue when it reports  results on May 6 (estimated) for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H17B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515274","title":"Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), PepGen Inc. (PEPG) and Omeros (OMER)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515274?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:40","pubTimestamp":1775047208,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Praxis Precision Medicines (PRAX), PepGen Inc. (PE...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-pepgen-inc-pepg-and-omeros-omer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-praxis-precision-medicines-prax-pepgen-inc-pepg-and-omeros-omer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","LABU","XBI","OMER","IE0009355771.USD","LU0320765992.SGD","XLV","BK4137","LU0029874061.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4581","HCSG","LU0109394709.USD","BK4588","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU0128526141.USD","BK4139","BK4007","BK4585","PEPG","LU0889565916.HKD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624532138","title":"PepGen Shares Fall After Data From Ongoing Phase 2 Study for Myotonic Dystrophy Type 1 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2624532138","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624532138?lang=en_us&edition=fundamental","pubTime":"2026-04-01 03:45","pubTimestamp":1774986303,"startTime":"0","endTime":"0","summary":"PepGen  shares fell about 59% in Tuesday trading after the company reported data from the lowest-dose cohort of its ongoing phase 2 FREEDOM2 study evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1.In patients treated at 5 mg/kg, mean splicing correction was 7.3% versus 6.8% with placebo, the company said late Monday, adding that mean splicing correction was 22.9% after excluding one outlier who exhibited a worsening in splicing correction of 70.8%.PGN-EDODM1 was generally well tolerated, with no serious adverse events, according to a statement.The company said dosing continues in the 10 mg/kg multiple ascending dose cohort, with data expected in the second half of 2026. Current cash should fund operations into the second half of 2027, it added.Price: 1.76, Change: -2.47, Percent Change: -58.39","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PEPG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623538514","title":"PepGen Is Maintained at Outperform by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2623538514","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623538514?lang=en_us&edition=fundamental","pubTime":"2026-03-31 22:41","pubTimestamp":1774968060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PEPG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 10:41 ET (14:41 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PEPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623744586","title":"Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623744586","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623744586?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:00","pubTimestamp":1774958444,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA) wit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-pepgen-inc-pepg-and-ideaya-biosciences-idya-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0029874061.USD","BK4585","BK4588","BK4581","PEPG","HCSG","BK4137","LU0128526141.USD","XLV","IDYA","LABU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pepgen.com","stockEarnings":[{"period":"1week","weight":-0.1353},{"period":"1month","weight":-0.1353},{"period":"3month","weight":-0.7835},{"period":"6month","weight":-0.7342},{"period":"1year","weight":-0.0455},{"period":"ytd","weight":-0.7742}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":0.0401},{"period":"3month","weight":0.0817},{"period":"6month","weight":0.1147},{"period":"1year","weight":0.2431},{"period":"ytd","weight":0.0832}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.057082},{"month":2,"riseRate":0.75,"avgChangeRate":0.580465},{"month":3,"riseRate":0,"avgChangeRate":-0.400307},{"month":4,"riseRate":0.5,"avgChangeRate":0.028304},{"month":5,"riseRate":0.25,"avgChangeRate":0.037198},{"month":6,"riseRate":0,"avgChangeRate":-0.194547},{"month":7,"riseRate":0.5,"avgChangeRate":-0.062921},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102699},{"month":9,"riseRate":0.25,"avgChangeRate":0.658187},{"month":10,"riseRate":0.75,"avgChangeRate":0.035806},{"month":11,"riseRate":0.5,"avgChangeRate":0.080021},{"month":12,"riseRate":0.5,"avgChangeRate":0.010709}],"exchange":"NASDAQ","name":"PepGen Inc.","nameEN":"PepGen Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"PepGen Inc.,PEPG,PepGen Inc.股票,PepGen Inc.股票老虎,PepGen Inc.股票老虎国际,PepGen Inc.行情,PepGen Inc.股票行情,PepGen Inc.股价,PepGen Inc.股市,PepGen Inc.股票价格,PepGen Inc.股票交易,PepGen Inc.股票购买,PepGen Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PepGen Inc.(PEPG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest PepGen Inc.(PEPG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction